Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Study summary

The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.

Ask AI to explain this study

Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedTrilaciclib and Saline (0.9% NaCl)

The study team can explain what participation involves.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 2, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 3

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Pharmacosmos A/S

Study sponsor

Study overview

What this study is about

Purpose: Supportive Care
Study type: Interventional
Phase: Phase 3
Sponsor: Pharmacosmos A/S
Interventions being studied: Drug: Trilaciclib; Drug: Saline (0.9% NaCl)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Small cell lung cancer (SCLC)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
Complete recovery from prior anti-tumor surgical procedures
Measurable and evaluable disease through tumor assessment
Willingness to participate and sign informed consent form

Reasons someone may not be able to joinExclusion criteria

Extensive Stage Small Cell Lung Cancer
Active cardiovascular disease
Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations
Pregnant or nursing women

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Pharmacosmos Investigational SiteOakland, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 2, 2026. Always confirm current availability with the study team.

View original record ↗